cui1,cui2,relation,name1,name2,type1,type2,weight,predicate
C0001047,C4055506,TREATS,Acetylcysteine,Accumulation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0001047,C4540229,TREATS,Acetylcysteine,Mitochondrial oxidative stress,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0001655,C0150312,TREATS,Corticotropin,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0001655,C4086268,TREATS,Corticotropin,Exacerbation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0001924,C0150312,TREATS,Albumins,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002059,C1704202,TREATS,Alkaline Phosphatase,Aspermia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002191,C0241863,TREATS,alpha 1-Antitrypsin,diabetic,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002191,C0332509,TREATS,alpha 1-Antitrypsin,Increased size (finding),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002199,C0221198,TREATS,Interferon-alpha,Lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002199,C0237677,TREATS,Interferon-alpha,insensitivity,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0002199,C0332149,TREATS,Interferon-alpha,Possible,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002199,C0332155,TREATS,Interferon-alpha,Did not receive therapy or drug for,aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0002199,C0424470,TREATS,Interferon-alpha,Undressed,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002199,C0439663,TREATS,Interferon-alpha,Infected,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0002199,C0562577,TREATS,Interferon-alpha,Mocking,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002199,C1545588,TREATS,Interferon-alpha,Protection,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002199,C1836348,TREATS,Interferon-alpha,Severe disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002199,C4321237,TREATS,Interferon-alpha,High Level,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002260,C0150312,TREATS,Eflornithine,Present,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0002520,C0038435,TREATS,Amino Acids,Stress,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002520,C0150312,TREATS,Amino Acids,Present,aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0002520,C0221198,TREATS,Amino Acids,Lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002520,C0332149,TREATS,Amino Acids,Possible,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002520,C0332461,TREATS,Amino Acids,Plaque (lesion),aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0002520,C0332575,TREATS,Amino Acids,Redness,aapp,fndg,13,TREATS_AAPPtrtsFNDG
C0002520,C0427184,TREATS,Amino Acids,No incoordination,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002520,C0439663,TREATS,Amino Acids,Infected,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002520,C0518609,TREATS,Amino Acids,consideration,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002520,C0557351,TREATS,Amino Acids,Employed,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002520,C0562577,TREATS,Amino Acids,Mocking,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002520,C0683954,TREATS,Amino Acids,research results,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002520,C0750484,TREATS,Amino Acids,Confirmation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002520,C1444656,TREATS,Amino Acids,Indicated,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002520,C1865782,TREATS,Amino Acids,CEREBELLAR DEGENERATION-RELATED AUTOANTIGEN 3,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002520,C1953367,TREATS,Amino Acids,Reference sequence,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0002520,C3843504,TREATS,Amino Acids,1 - 3,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002520,C4321237,TREATS,Amino Acids,High Level,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0002525,C0392209,TREATS,"Amino Acids, Essential",Nutritional status,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003009,C0150312,TREATS,angiotensin II,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003009,C1882086,TREATS,angiotensin II,New York Heart Association Class III,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003018,C0086565,TREATS,Angiotensins,Liver Dysfunction,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003250,C0085393,TREATS,Monoclonal Antibodies,Immunocompromised Host,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003250,C0439662,TREATS,Monoclonal Antibodies,Immune,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003442,C0020649,TREATS,"Lymphocyte Immune Globulin, Anti-Thymocyte Globulin",Hypotension,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003442,C0039231,TREATS,"Lymphocyte Immune Globulin, Anti-Thymocyte Globulin",Tachycardia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003442,C0497365,TREATS,"Lymphocyte Immune Globulin, Anti-Thymocyte Globulin",Generalized rash,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003442,C3273245,TREATS,"Lymphocyte Immune Globulin, Anti-Thymocyte Globulin",Acute Rejection,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003641,C0150312,TREATS,Aprotinin,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003765,C0332516,TREATS,Arginine,Symmetrical,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003765,C0332575,TREATS,Arginine,Redness,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003993,C0150312,TREATS,ASPARAGINASE,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0003993,C0442797,TREATS,ASPARAGINASE,Decreasing,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0004609,C0026826,TREATS,Baclofen,Muscle Hypertonia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0005789,C0020672,TREATS,Blood Coagulation Factor,"Hypothermia, natural",aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0006050,C0150312,TREATS,Botulinum Toxin Type A,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0006050,C0429807,TREATS,Botulinum Toxin Type A,Bladder capacity,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0006055,C2674421,TREATS,Botulinum Toxins,Jerking movements,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0006217,C0015663,TREATS,Bromelains,Fasting,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0006217,C0150312,TREATS,Bromelains,Present,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0006217,C0600457,TREATS,Bromelains,Gravidity,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0006938,C0150312,TREATS,Captopril,Present,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0006938,C0205161,TREATS,Captopril,Abnormal,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0006938,C3887644,TREATS,Captopril,Inflammatory infiltrate,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0007258,C1704202,TREATS,Carnitine,Aspermia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0007332,C0239987,TREATS,Caseins,Deceased IgG,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0008742,C0150312,TREATS,CHYMOTRYPSIN,Present,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0008742,C1444656,TREATS,CHYMOTRYPSIN,Indicated,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0009325,C0221198,TREATS,Collagen,Lesion,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0009325,C0332155,TREATS,Collagen,Did not receive therapy or drug for,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0009325,C0577059,TREATS,Collagen,Liver normal,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0009325,C1444662,TREATS,Collagen,Discontinued,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0010592,C0035648,TREATS,Cyclosporine,risk factors,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0010592,C0679246,TREATS,Cyclosporine,advanced disease,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0010592,C3272283,TREATS,Cyclosporine,American College of Cardiology/American Heart Association Lesion Complexity Score C,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0010592,C3273245,TREATS,Cyclosporine,Acute Rejection,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0012020,C0038435,TREATS,Diazooxonorleucine,Stress,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0012020,C0150312,TREATS,Diazooxonorleucine,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0012020,C0231162,TREATS,Diazooxonorleucine,Normal general body function,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0012020,C3842953,TREATS,Diazooxonorleucine,> 24 hrs,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0014025,C0332155,TREATS,Enalapril,Did not receive therapy or drug for,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0014027,C0086565,TREATS,Enalaprilat,Liver Dysfunction,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0014027,C4013784,TREATS,Enalaprilat,"Hypertension, severe",aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0014822,C1821244,TREATS,Erythropoietin,Normal development,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015528,C0150312,TREATS,factor XIII,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015879,C0014745,TREATS,Ferritin,Palmar erythema,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015879,C1545588,TREATS,Ferritin,Protection,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0015879,C1836348,TREATS,Ferritin,Severe disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015879,C3806166,TREATS,Ferritin,Poor outcome,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015980,C0003962,TREATS,Interferon-beta,Ascites,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0015980,C0038435,TREATS,Interferon-beta,Stress,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015980,C0150312,TREATS,Interferon-beta,Present,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0015980,C0332149,TREATS,Interferon-beta,Possible,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015980,C0332155,TREATS,Interferon-beta,Did not receive therapy or drug for,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015980,C0439663,TREATS,Interferon-beta,Infected,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015980,C0562577,TREATS,Interferon-beta,Mocking,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015980,C1545588,TREATS,Interferon-beta,Protection,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015980,C3272903,TREATS,Interferon-beta,Overall Response,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015980,C3842673,TREATS,Interferon-beta,Day 6,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015980,C4055506,TREATS,Interferon-beta,Accumulation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015982,C0150312,TREATS,Fibrin,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0015982,C0332575,TREATS,Fibrin,Redness,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0016006,C0241863,TREATS,Fibrinogen,diabetic,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0016006,C0424561,TREATS,Fibrinogen,Bleeds profusely,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0016006,C3843309,TREATS,Fibrinogen,1 time,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0016006,C4086268,TREATS,Fibrinogen,Exacerbation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0017687,C4018909,TREATS,Glucagon,Overdose,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0017797,C0150312,TREATS,Glutamine,Present,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0017797,C0750484,TREATS,Glutamine,Confirmation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0017797,C1832073,TREATS,Glutamine,Handling,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0017890,C0150312,TREATS,Glycine,Present,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0017976,C0442748,TREATS,Glycoside Hydrolases,6/4,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0017976,C0750558,TREATS,Glycoside Hydrolases,Unlikely,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0018061,C3540840,TREATS,Gonadotropins,Sign or Symptom,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0019602,C0150312,TREATS,Histidine,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0019602,C0332575,TREATS,Histidine,Redness,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0019602,C0427184,TREATS,Histidine,No incoordination,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0019602,C0728725,TREATS,Histidine,Low pH,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0019602,C1519789,TREATS,Histidine,Unexpected Adverse Event,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0020388,C0221198,TREATS,Hydroxyproline,Lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0020388,C4054143,TREATS,Hydroxyproline,Pulmonary Compliance,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0020731,C0600457,TREATS,Pertussis Toxin,Gravidity,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0020852,C0562577,TREATS,Immunoglobulin G,Mocking,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0020852,C0750484,TREATS,Immunoglobulin G,Confirmation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0020960,C0150312,TREATS,Immune Sera,Present,aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0020960,C0439662,TREATS,Immune Sera,Immune,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0020960,C0439663,TREATS,Immune Sera,Infected,aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0020960,C0442726,TREATS,Immune Sera,Detected (finding),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0020960,C0562577,TREATS,Immune Sera,Mocking,aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0020960,C0750479,TREATS,Immune Sera,blank,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0020960,C0750484,TREATS,Immune Sera,Confirmation,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0020960,C1262477,TREATS,Immune Sera,Weight decreased,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0020960,C1318963,TREATS,Immune Sera,Readiness,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0020960,C1545588,TREATS,Immune Sera,Protection,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0020960,C1859430,TREATS,Immune Sera,Life-threatening infections,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0021641,C0017979,TREATS,Insulin,Glycosuria,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021641,C0020461,TREATS,Insulin,Hyperkalemia,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0021641,C0150312,TREATS,Insulin,Present,aapp,fndg,10,TREATS_AAPPtrtsFNDG
C0021641,C0241863,TREATS,Insulin,diabetic,aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0021641,C0442757,TREATS,Insulin,3/4,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021641,C0580545,TREATS,Insulin,Blood glucose normal,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021641,C0595877,TREATS,Insulin,Blood glucose increased,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021641,C0750484,TREATS,Insulin,Confirmation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021641,C0861023,TREATS,Insulin,insulin low,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021641,C1881358,TREATS,Insulin,Large Mass,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021641,C3714738,TREATS,Insulin,Compliance,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021641,C4288557,TREATS,Insulin,One Activity Hour,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021740,C0038187,TREATS,Recombinant Interferon-gamma,Starvation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021740,C0150312,TREATS,Recombinant Interferon-gamma,Present,aapp,fndg,6,TREATS_AAPPtrtsFNDG
C0021740,C0221198,TREATS,Recombinant Interferon-gamma,Lesion,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0021740,C0748025,TREATS,Recombinant Interferon-gamma,Low protein level,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021740,C3845593,TREATS,Recombinant Interferon-gamma,Major change,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021740,C3845876,TREATS,Recombinant Interferon-gamma,Consequent,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0021740,C4313322,TREATS,Recombinant Interferon-gamma,Alveolar damage,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021740,C4321237,TREATS,Recombinant Interferon-gamma,High Level,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021743,C0150312,TREATS,Interferon Type I,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021743,C0436345,TREATS,Interferon Type I,Symptom severe,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021747,C0020580,TREATS,Interferons,Hypesthesia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021747,C0085639,TREATS,Interferons,Falls,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021747,C0150312,TREATS,Interferons,Present,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0021747,C0205160,TREATS,Interferons,Negative,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0021747,C0221198,TREATS,Interferons,Lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021747,C0332149,TREATS,Interferons,Possible,aapp,fndg,5,TREATS_AAPPtrtsFNDG
C0021747,C0332575,TREATS,Interferons,Redness,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021747,C0439662,TREATS,Interferons,Immune,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0021747,C0439663,TREATS,Interferons,Infected,aapp,fndg,6,TREATS_AAPPtrtsFNDG
C0021747,C0581126,TREATS,Interferons,Severe asthma,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021747,C0683521,TREATS,Interferons,patient condition,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021747,C0750479,TREATS,Interferons,blank,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021747,C0750558,TREATS,Interferons,Unlikely,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021747,C1299586,TREATS,Interferons,Has difficulty doing (qualifier value),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021747,C1444662,TREATS,Interferons,Discontinued,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0021747,C1709157,TREATS,Interferons,Negative Surgical Margin,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021747,C1836348,TREATS,Interferons,Severe disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021747,C1857434,TREATS,Interferons,Pulmonary blebs,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021747,C1858576,TREATS,Interferons,Heterogeneous disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021747,C3540840,TREATS,Interferons,Sign or Symptom,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0021747,C3811922,TREATS,Interferons,Liver transplant recipient,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021747,C3816499,TREATS,Interferons,Pathogenic,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021747,C3841448,TREATS,Interferons,Much worse,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021747,C3843647,TREATS,Interferons,> 2 years,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021747,C3844397,TREATS,Interferons,Initial screen,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021747,C3872830,TREATS,Interferons,Inflammatory lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021747,C4050171,TREATS,Interferons,Sustained Virologic Response,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021747,C4086268,TREATS,Interferons,Exacerbation,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0021760,C0038187,TREATS,Interleukin-6,Starvation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021760,C0150312,TREATS,Interleukin-6,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0021764,C0439663,TREATS,Interleukins,Infected,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0022192,C0184512,TREATS,Isoleucine,Stabilized (qualifier value),aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0022192,C1113650,TREATS,Isoleucine,brain morphology,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0023401,C0150312,TREATS,Leucine,Present,aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0023401,C0332575,TREATS,Leucine,Redness,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0023607,C3843058,TREATS,Luteinizing Hormone,First half,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0023610,C0085639,TREATS,Gonadorelin,Falls,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0023610,C1832073,TREATS,Gonadorelin,Handling,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0023764,C0021294,TREATS,Lipase,"Infant, Premature",aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0023764,C0231221,TREATS,Lipase,Asymptomatic,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0023764,C3841253,TREATS,Lipase,Reusable,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0024337,C0150312,TREATS,Lysine,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0024337,C0332575,TREATS,Lysine,Redness,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0024337,C0427184,TREATS,Lysine,No incoordination,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0025646,C0150312,TREATS,Methionine,Present,aapp,fndg,9,TREATS_AAPPtrtsFNDG
C0025646,C0332155,TREATS,Methionine,Did not receive therapy or drug for,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0025646,C0439663,TREATS,Methionine,Infected,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0025646,C3843058,TREATS,Methionine,First half,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0025646,C4288085,TREATS,Methionine,Two to Five Activity Hours,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0025741,C0021294,TREATS,Methyldopa,"Infant, Premature",aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0025741,C0231191,TREATS,Methyldopa,Idiosyncrasy,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0026794,C0150312,TREATS,Muramidase,Present,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0026794,C4018909,TREATS,Muramidase,Overdose,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0027597,C0150312,TREATS,Zinostatin,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0027597,C0240341,TREATS,Zinostatin,Micrographia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0028833,C0020621,TREATS,Octreotide,Hypokalemia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0028833,C0425945,TREATS,Octreotide,Prolonged menses,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0030095,C0043094,TREATS,Oxytocin,Weight Gain,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0030095,C0150312,TREATS,Oxytocin,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0030817,C0033687,TREATS,Penicillamine,Proteinuria,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0030817,C0035648,TREATS,Penicillamine,risk factors,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0030817,C0277854,TREATS,Penicillamine,dyspneic,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0030817,C0577053,TREATS,Penicillamine,Lesion of liver,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0030946,C0150312,TREATS,Endopeptidases,Present,aapp,fndg,13,TREATS_AAPPtrtsFNDG
C0030946,C0184512,TREATS,Endopeptidases,Stabilized (qualifier value),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0030946,C0332149,TREATS,Endopeptidases,Possible,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0030946,C0332575,TREATS,Endopeptidases,Redness,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0030946,C0439663,TREATS,Endopeptidases,Infected,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0030946,C0679217,TREATS,Endopeptidases,active state,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0031453,C0332575,TREATS,Phenylalanine,Redness,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0031453,C0549649,TREATS,Phenylalanine,MISUSE,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0032143,C0041667,TREATS,alteplase,Underweight,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0032143,C0150312,TREATS,alteplase,Present,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0032143,C0241863,TREATS,alteplase,diabetic,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0032143,C0332155,TREATS,alteplase,Did not receive therapy or drug for,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0032143,C0422837,TREATS,alteplase,Neurological observations,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0032143,C0562577,TREATS,alteplase,Mocking,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0032143,C1299448,TREATS,alteplase,Patient ventilated,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0032143,C2959885,TREATS,alteplase,Microthrombus,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0032144,C0574941,TREATS,Plasminogen Activator,Inflamed joint,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0033621,C0683954,TREATS,Protein C,research results,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0034862,C0150312,TREATS,"Vaccines, Recombinant",Present,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0034862,C0439663,TREATS,"Vaccines, Recombinant",Infected,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0034862,C0562577,TREATS,"Vaccines, Recombinant",Mocking,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0034862,C1444783,TREATS,"Vaccines, Recombinant",Instability,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0034862,C1545588,TREATS,"Vaccines, Recombinant",Protection,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0034862,C2945640,TREATS,"Vaccines, Recombinant",compromise,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0036002,C0150312,TREATS,S-Adenosylmethionine,Present,aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0036002,C0332575,TREATS,S-Adenosylmethionine,Redness,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0036720,C0280457,TREATS,Serine,"site, metastatic cancer",aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0036720,C0332575,TREATS,Serine,Redness,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0036720,C0679218,TREATS,Serine,Resting state,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0036720,C1519789,TREATS,Serine,Unexpected Adverse Event,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0037659,C0015663,TREATS,Somatostatin,Fasting,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0037659,C0150312,TREATS,Somatostatin,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0037659,C0232341,TREATS,Somatostatin,Increased vascular flow,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0038838,C0150312,TREATS,Superoxide Dismutase,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0039617,C0332461,TREATS,tetanus toxin,Plaque (lesion),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0040005,C0332575,TREATS,Threonine,Redness,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0040005,C0679218,TREATS,Threonine,Resting state,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0040005,C1519789,TREATS,Threonine,Unexpected Adverse Event,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0040018,C0150312,TREATS,Thrombin,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0040106,C0679250,TREATS,Thymosin,Disease Outcome,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0040498,C0150312,TREATS,Tosylphenylalanyl Chloromethyl Ketone,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0040690,C0038187,TREATS,Transforming Growth Factor beta,Starvation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041236,C0086439,TREATS,TRYPSIN,Hypokinesia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041236,C0150312,TREATS,TRYPSIN,Present,aapp,fndg,26,TREATS_AAPPtrtsFNDG
C0041236,C0332155,TREATS,TRYPSIN,Did not receive therapy or drug for,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0041236,C0425945,TREATS,TRYPSIN,Prolonged menses,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041236,C0456913,TREATS,TRYPSIN,Cold medium,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041236,C0562577,TREATS,TRYPSIN,Mocking,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0041236,C0728725,TREATS,TRYPSIN,Low pH,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0041236,C1290905,TREATS,TRYPSIN,Discrepancy,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041236,C1444656,TREATS,TRYPSIN,Indicated,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041236,C3842675,TREATS,TRYPSIN,Day 3,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041236,C4321237,TREATS,TRYPSIN,High Level,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0041242,C0150312,TREATS,Trypsin Inhibitors,Present,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0041242,C0332575,TREATS,Trypsin Inhibitors,Redness,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041249,C0038435,TREATS,Tryptophan,Stress,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041249,C0150312,TREATS,Tryptophan,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041249,C0332575,TREATS,Tryptophan,Redness,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041249,C1865782,TREATS,Tryptophan,CEREBELLAR DEGENERATION-RELATED AUTOANTIGEN 3,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041485,C0332575,TREATS,Tyrosine,Redness,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041485,C1865782,TREATS,Tyrosine,CEREBELLAR DEGENERATION-RELATED AUTOANTIGEN 3,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0041485,C1953367,TREATS,Tyrosine,Reference sequence,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042071,C0150312,TREATS,Urokinase,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042071,C0574941,TREATS,Urokinase,Inflamed joint,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042413,C0020649,TREATS,Vasopressins,Hypotension,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042413,C0150312,TREATS,Vasopressins,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042413,C0232341,TREATS,Vasopressins,Increased vascular flow,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042413,C0241311,TREATS,Vasopressins,post operative (finding),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0042971,C0241863,TREATS,von Willebrand factor,diabetic,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0051846,C0205400,TREATS,angiopeptin,Thickened,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0052897,C0683337,TREATS,bactericidal permeability increasing protein,late disease stage,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0053355,C0332155,TREATS,ubenimex,Did not receive therapy or drug for,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0054534,C4021734,TREATS,calpastatin,Abnormality of mitochondrial metabolism,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0057002,C1836348,TREATS,cytomegalovirus immune globulin,Severe disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0057256,C0679250,TREATS,Defensins,Disease Outcome,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0057256,C2673622,TREATS,Defensins,Mucosal lesions,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0059406,C0349790,TREATS,Eosinophil Major Basic Protein,Exacerbation of asthma,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0062525,C0033213,TREATS,hepatitis B immune globulin,Problem,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0062525,C0239998,TREATS,hepatitis B immune globulin,Recurrent infections,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0062525,C3272281,TREATS,hepatitis B immune globulin,American College of Cardiology/American Heart Association Lesion Complexity Score A,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0064858,C0150312,TREATS,leupeptin,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0064858,C4055506,TREATS,leupeptin,Accumulation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0065374,C0376618,TREATS,Lisinopril,Endotoxemia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0065374,C1545588,TREATS,Lisinopril,Protection,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0073870,C4055506,TREATS,S-ethyl glutathione,Accumulation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0074926,C0439663,TREATS,Soy Proteins,Infected,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0078080,C0150312,TREATS,"vasopressin, 1-(1-mercaptocyclohexaneacetic acid)-2-(O- methyl-L-tyrosine)-8-L-arginine-",Present,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0079189,C0332575,TREATS,cytokine,Redness,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0079189,C4086268,TREATS,cytokine,Exacerbation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0079633,C3843265,TREATS,Interleukin-8,Line 2,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0080225,C0150312,TREATS,Thymopentin,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0083183,C0232459,TREATS,Lactase,Abnormal digestive tract function,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0083220,C0085639,TREATS,deslorelin,Falls,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0084178,C0150312,TREATS,prohibitin,Present,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0085295,C0038187,TREATS,Interleukin-10,Starvation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0027854,TREATS,"Immunoglobulins, Intravenous",Neurologic Manifestations,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0035648,TREATS,"Immunoglobulins, Intravenous",risk factors,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0085393,TREATS,"Immunoglobulins, Intravenous",Immunocompromised Host,aapp,fndg,6,TREATS_AAPPtrtsFNDG
C0085297,C0150312,TREATS,"Immunoglobulins, Intravenous",Present,aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0085297,C0231224,TREATS,"Immunoglobulins, Intravenous",Crisis,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0239998,TREATS,"Immunoglobulins, Intravenous",Recurrent infections,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0241526,TREATS,"Immunoglobulins, Intravenous",Unresponsiveness,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0241863,TREATS,"Immunoglobulins, Intravenous",diabetic,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0277797,TREATS,"Immunoglobulins, Intravenous",Apyrexial,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0332149,TREATS,"Immunoglobulins, Intravenous",Possible,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0425710,TREATS,"Immunoglobulins, Intravenous",Peripheral perfusion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0425945,TREATS,"Immunoglobulins, Intravenous",Prolonged menses,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0436345,TREATS,"Immunoglobulins, Intravenous",Symptom severe,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0481667,TREATS,"Immunoglobulins, Intravenous",Live Birth,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0518609,TREATS,"Immunoglobulins, Intravenous",consideration,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0743630,TREATS,"Immunoglobulins, Intravenous",exacerbation acute,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0750394,TREATS,"Immunoglobulins, Intravenous",White blood cell count decreased,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0750484,TREATS,"Immunoglobulins, Intravenous",Confirmation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0750558,TREATS,"Immunoglobulins, Intravenous",Unlikely,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C0920247,TREATS,"Immunoglobulins, Intravenous",Rubeola exposure,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C1263979,TREATS,"Immunoglobulins, Intravenous",Severe cytopenia,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0085297,C1457868,TREATS,"Immunoglobulins, Intravenous",Worse,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C1836348,TREATS,"Immunoglobulins, Intravenous",Severe disorder,aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0085297,C1998827,TREATS,"Immunoglobulins, Intravenous",Respiratory Status,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C2826210,TREATS,"Immunoglobulins, Intravenous",Complete Recovery,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C2945640,TREATS,"Immunoglobulins, Intravenous",compromise,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0085297,C3272283,TREATS,"Immunoglobulins, Intravenous",American College of Cardiology/American Heart Association Lesion Complexity Score C,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C3274777,TREATS,"Immunoglobulins, Intravenous",Severely Abnormal Ventricular Ejection Fraction,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C3806482,TREATS,"Immunoglobulins, Intravenous",Recurrent respiratory infections,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0085297,C3830314,TREATS,"Immunoglobulins, Intravenous",Enhancing Lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C3843196,TREATS,"Immunoglobulins, Intravenous",3 to 5 days,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C4054987,TREATS,"Immunoglobulins, Intravenous",Favorable Response,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085297,C4321237,TREATS,"Immunoglobulins, Intravenous",High Level,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085379,C0035648,TREATS,Muromonab-CD3,risk factors,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085379,C0150312,TREATS,Muromonab-CD3,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085379,C0742904,TREATS,Muromonab-CD3,creatinine rising,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085379,C3273245,TREATS,Muromonab-CD3,Acute Rejection,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085379,C3280504,TREATS,Muromonab-CD3,Crypt hyperplasia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0085741,C0442797,TREATS,"Pancreatic Trypsin Secretory Inhibitor, Kazal",Decreasing,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0103306,C0150312,TREATS,angiotensin I (1-7),Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0103306,C0497247,TREATS,angiotensin I (1-7),Increase in blood pressure,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0109081,C3834249,TREATS,Ceredase,Unlimited,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0123759,C0150312,TREATS,Interleukin-12,Present,aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0123759,C0574941,TREATS,Interleukin-12,Inflamed joint,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0123759,C3842673,TREATS,Interleukin-12,Day 6,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0123759,C4321237,TREATS,Interleukin-12,High Level,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0162745,C0154270,TREATS,COLLAGENASE,Localized adiposity,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0164613,C0238983,TREATS,interferon alfacon-1,Chest deformity,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0169964,C0332149,TREATS,Somatropin,Possible,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0172511,C0150312,TREATS,interferon-alpha 8,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0210630,C0038002,TREATS,Filgrastim,Splenomegaly,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0210638,C0428648,TREATS,Alveofact,Inspired oxygen concentration,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0244713,C0439662,TREATS,interferon beta-1b,Immune,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0245109,C0027854,TREATS,anakinra,Neurologic Manifestations,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0245109,C0150312,TREATS,anakinra,Present,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0245109,C0221198,TREATS,anakinra,Lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0245109,C0332155,TREATS,anakinra,Did not receive therapy or drug for,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0245109,C0376618,TREATS,anakinra,Endotoxemia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0245109,C0439662,TREATS,anakinra,Immune,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0245109,C0455205,TREATS,anakinra,Skin finding,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0245109,C0562577,TREATS,anakinra,Mocking,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0245109,C0700292,TREATS,anakinra,Hypoxemia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0245109,C1260922,TREATS,anakinra,Abnormal breathing,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0245109,C1299586,TREATS,anakinra,Has difficulty doing (qualifier value),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0245109,C1444656,TREATS,anakinra,Indicated,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0245109,C1836721,TREATS,anakinra,"MALARIA, MILD, SUSCEPTIBILITY TO",aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0245109,C3890735,TREATS,anakinra,Complete Response with Incomplete Platelet Recovery,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0254610,C0574941,TREATS,Interleukin-15,Inflamed joint,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0254781,C0221198,TREATS,3-chlorotyrosine,Lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0280485,C0150312,TREATS,m-azidopyrimethamine,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0301521,C0332149,TREATS,therapeutic vaccine,Possible,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0301521,C4055223,TREATS,therapeutic vaccine,Clinical Response,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0304925,C0150312,TREATS,"Albumin Human, USP",Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0305052,C0150312,TREATS,Gamma globulin serum,Present,aapp,fndg,7,TREATS_AAPPtrtsFNDG
C0305052,C0332155,TREATS,Gamma globulin serum,Did not receive therapy or drug for,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0305052,C0332575,TREATS,Gamma globulin serum,Redness,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0305052,C0439663,TREATS,Gamma globulin serum,Infected,aapp,fndg,5,TREATS_AAPPtrtsFNDG
C0305052,C0562577,TREATS,Gamma globulin serum,Mocking,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0305052,C0600457,TREATS,Gamma globulin serum,Gravidity,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0305052,C4050171,TREATS,Gamma globulin serum,Sustained Virologic Response,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0308550,C0221198,TREATS,BRSV,Lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0309234,C0424670,TREATS,HVT,Weight for height,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0310756,C0241334,TREATS,Parainfluenza 3 vaccine,TEMPERATE CLIMATE,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0310969,C0150312,TREATS,Escherichia coli antibody,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0311461,C0150312,TREATS,Nonessential amino acid,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0312636,C0085393,TREATS,Antibody to hepatitis E virus,Immunocompromised Host,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0358321,C0442797,TREATS,Immune Globulin (Human),Decreasing,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0358321,C0581126,TREATS,Immune Globulin (Human),Severe asthma,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0358321,C1514815,TREATS,Immune Globulin (Human),Refractory Disease,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0358321,C1861874,TREATS,Immune Globulin (Human),Severe atopic dermatitis,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0358321,C2826244,TREATS,Immune Globulin (Human),Life Threatening,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0359168,C0150312,TREATS,Mouse monoclonal antibody,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0359180,C0150312,TREATS,Albumin solution,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0377091,C0150312,TREATS,Glycopeptidase F,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0379135,C0743150,TREATS,Becaplermin,diabetic ulcer,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0383429,C0332149,TREATS,alemtuzumab,Possible,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0383429,C1836348,TREATS,alemtuzumab,Severe disorder,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0383429,C3272903,TREATS,alemtuzumab,Overall Response,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0383429,C3273245,TREATS,alemtuzumab,Acute Rejection,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0383779,C0562577,TREATS,benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone,Mocking,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0391001,C1444662,TREATS,peginterferon alfa-2a,Discontinued,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0393022,C0150312,TREATS,rituximab,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0393022,C0264939,TREATS,rituximab,Systemic Vasculitis,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0393022,C0332149,TREATS,rituximab,Possible,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0393022,C0544452,TREATS,rituximab,Disease remission,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0393022,C0743630,TREATS,rituximab,exacerbation acute,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0393022,C1333400,TREATS,rituximab,Gadolinium-Enhancing Lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0393022,C1521726,TREATS,rituximab,partial response,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0393022,C1560152,TREATS,rituximab,CTCAE Grade 4 Vasculitis,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0393022,C1853237,TREATS,rituximab,Isolated cases,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0393022,C1962917,TREATS,rituximab,High grade (lymphoma grade) (finding),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0393022,C3272283,TREATS,rituximab,American College of Cardiology/American Heart Association Lesion Complexity Score C,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0393022,C3272903,TREATS,rituximab,Overall Response,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0393022,C4014164,TREATS,rituximab,Lymphoproliferation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0393022,C4055223,TREATS,rituximab,Clinical Response,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0457610,C0150312,TREATS,Measles-rubella vaccine (live),Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0457610,C0427184,TREATS,Measles-rubella vaccine (live),No incoordination,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0457610,C0679218,TREATS,Measles-rubella vaccine (live),Resting state,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0537439,C0150312,TREATS,enfuvirtide,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0537439,C0439663,TREATS,enfuvirtide,Infected,aapp,fndg,4,TREATS_AAPPtrtsFNDG
C0537894,C1836348,TREATS,Caspofungin,Severe disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0538777,C4321237,TREATS,ancestim,High Level,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0544420,C0150312,TREATS,Digestive Enzymes,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0592527,C0150312,TREATS,Betaferon,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0594372,C0750484,TREATS,Avonex,Confirmation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0597418,C1545588,TREATS,Rotavirus Vaccines,Protection,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0664336,C0574941,TREATS,survivin,Inflamed joint,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0666743,C0021294,TREATS,infliximab,"Infant, Premature",aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0666743,C0150312,TREATS,infliximab,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0666743,C0749075,TREATS,infliximab,STRUCTURAL Abnormalities,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0666743,C1859543,TREATS,infliximab,Severe colitis,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0666743,C3842672,TREATS,infliximab,Day 7,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0672596,C0021294,TREATS,palivizumab,"Infant, Premature",aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0672596,C0085393,TREATS,palivizumab,Immunocompromised Host,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0672596,C0419437,TREATS,palivizumab,High risk infant,aapp,fndg,8,TREATS_AAPPtrtsFNDG
C0672596,C3272283,TREATS,palivizumab,American College of Cardiology/American Heart Association Lesion Complexity Score C,aapp,fndg,7,TREATS_AAPPtrtsFNDG
C0677829,C0743150,TREATS,Palifermin,diabetic ulcer,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0700607,C2826244,TREATS,digoxin antibodies Fab fragments,Life Threatening,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0700607,C4018909,TREATS,digoxin antibodies Fab fragments,Overdose,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0717758,C0150312,TREATS,Etanercept,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0717758,C0221198,TREATS,Etanercept,Lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0717758,C1444662,TREATS,Etanercept,Discontinued,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0719605,C1836348,TREATS,Cytogam,Severe disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0724601,C0241863,TREATS,"Insulin, Regular, Pork",diabetic,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0728747,C3843385,TREATS,trastuzumab,36+ months,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0751599,C0332509,TREATS,Recombinant Interferon Beta,Increased size (finding),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0751599,C4086268,TREATS,Recombinant Interferon Beta,Exacerbation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0795657,C1320226,TREATS,"alpha 1-proteinase inhibitor, human",Incubation period,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0796392,C0442797,TREATS,bevacizumab,Decreasing,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0796392,C2825972,TREATS,bevacizumab,Cant,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0887943,C1545588,TREATS,alpha-Defensins,Protection,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0911901,C0150312,TREATS,benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0913823,C0556025,TREATS,peptide C34,Injecting drug user,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0966225,C0349790,TREATS,omalizumab,Exacerbation of asthma,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0966225,C0581126,TREATS,omalizumab,Severe asthma,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0966225,C4086268,TREATS,omalizumab,Exacerbation,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C0969324,C0150312,TREATS,mepolizumab,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0969324,C0349790,TREATS,mepolizumab,Exacerbation of asthma,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0969324,C0581124,TREATS,mepolizumab,Mild asthma,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0969324,C0581126,TREATS,mepolizumab,Severe asthma,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C0969324,C4086268,TREATS,mepolizumab,Exacerbation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0982327,C0221198,TREATS,PEGINTERFERON,Lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0995188,C0278252,TREATS,cetuximab,Prognosis bad,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C0995188,C0332149,TREATS,cetuximab,Possible,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C1122087,C3840775,TREATS,adalimumab,Anticipated,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1135662,C0700292,TREATS,Dornase Alfa,Hypoxemia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1135662,C1299448,TREATS,Dornase Alfa,Patient ventilated,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1138321,C0235896,TREATS,glutoxim,Pulmonary Infiltrate,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1170000,C3272283,TREATS,drotrecogin alfa,American College of Cardiology/American Heart Association Lesion Complexity Score C,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C1171255,C0184511,TREATS,Humira,Improved,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1172734,C0221198,TREATS,natalizumab,Lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1172734,C0333361,TREATS,natalizumab,Acute inflammation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1172734,C1833300,TREATS,natalizumab,White matter changes,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1172734,C1855010,TREATS,natalizumab,Progressive leukoencephalopathy,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1335439,C0150312,TREATS,Polymerase,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1367202,C3273948,TREATS,ipilimumab,Pseudoprogression,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1448177,C0038187,TREATS,"TNF protein, human",Starvation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1448177,C0150312,TREATS,"TNF protein, human",Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1448177,C0221198,TREATS,"TNF protein, human",Lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1455498,C0150312,TREATS,"TYRP1 protein, human",Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1512511,C0221198,TREATS,Human Papilloma Virus Vaccine,Lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1515370,C1262477,TREATS,Recombinant Fas Ligand,Weight decreased,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1515370,C3476546,TREATS,Recombinant Fas Ligand,Symptoms score,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1515370,C4313322,TREATS,Recombinant Fas Ligand,Alveolar damage,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1517683,C4484175,TREATS,L-Selenomethionine,Growth phase,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1522712,C0231221,TREATS,Recombinant Interferon-alpha Inducible Protein 10,Asymptomatic,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1522712,C0439663,TREATS,Recombinant Interferon-alpha Inducible Protein 10,Infected,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1522712,C1836348,TREATS,Recombinant Interferon-alpha Inducible Protein 10,Severe disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1522712,C3843265,TREATS,Recombinant Interferon-alpha Inducible Protein 10,Line 2,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1527233,C0150312,TREATS,Recombinant Immune Globulin,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1527233,C0439662,TREATS,Recombinant Immune Globulin,Immune,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1527233,C0439663,TREATS,Recombinant Immune Globulin,Infected,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1527233,C0521874,TREATS,Recombinant Immune Globulin,Victim of neglect (finding),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1527233,C1832073,TREATS,Recombinant Immune Globulin,Handling,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1541483,C0027854,TREATS,eculizumab,Neurologic Manifestations,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1541483,C2983415,TREATS,eculizumab,Persistent Disease,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1564892,C1262477,TREATS,Complement Inactivating Agents,Weight decreased,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C0020649,TREATS,tocilizumab,Hypotension,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C0221198,TREATS,tocilizumab,Lesion,aapp,fndg,4,TREATS_AAPPtrtsFNDG
C1609165,C0424755,TREATS,tocilizumab,Fever symptoms (finding),aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C0436345,TREATS,tocilizumab,Symptom severe,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C0518609,TREATS,tocilizumab,consideration,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C0580545,TREATS,tocilizumab,Blood glucose normal,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C1609165,C0700292,TREATS,tocilizumab,Hypoxemia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C0743630,TREATS,tocilizumab,exacerbation acute,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C0750484,TREATS,tocilizumab,Confirmation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C1299448,TREATS,tocilizumab,Patient ventilated,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C1836348,TREATS,tocilizumab,Severe disorder,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C1609165,C1850165,TREATS,tocilizumab,Elevated IL6,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C1609165,C3540840,TREATS,tocilizumab,Sign or Symptom,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C3890735,TREATS,tocilizumab,Complete Response with Incomplete Platelet Recovery,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609165,C4321237,TREATS,tocilizumab,High Level,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C1609931,C0020649,TREATS,siltuximab,Hypotension,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1609931,C0205160,TREATS,siltuximab,Negative,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C1619966,C0424595,TREATS,abatacept,Undifferentiated illness,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1701084,C0150312,TREATS,"CD9 protein, human",Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1707382,C4053862,TREATS,bavituximab,Virologic Response,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1723401,C3280118,TREATS,belimumab,Mild disorder,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1831854,C0150312,TREATS,catumaxomab,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C1832027,C0086439,TREATS,ofatumumab,Hypokinesia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2003387,C0085393,TREATS,DAS181,Immunocompromised Host,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C2003387,C1836348,TREATS,DAS181,Severe disorder,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C2003387,C3842674,TREATS,DAS181,Day 5,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2346819,C0516981,TREATS,tanezumab,Physical function,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2352806,C0151723,TREATS,necitumumab,Hypomagnesemia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2353893,C0581126,TREATS,golimumab,Severe asthma,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2608641,C0686750,TREATS,ACAM2000,Well adult,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2698127,C4055506,TREATS,Anti-CD25 Monoclonal Antibody,Accumulation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2702333,C0150312,TREATS,"Immunoglobulin G, Human",Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2719767,C0429810,TREATS,onabotulinumtoxinA,Bladder compliance,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2719767,C0429826,TREATS,onabotulinumtoxinA,Dysfunctional voiding of urine,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2719767,C0442797,TREATS,onabotulinumtoxinA,Decreasing,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2742797,C1859543,TREATS,vedolizumab,Severe colitis,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2935150,C0231221,TREATS,solanezumab,Asymptomatic,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2981360,C4086268,TREATS,lebrikizumab,Exacerbation,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C2981360,C4321237,TREATS,lebrikizumab,High Level,aapp,fndg,3,TREATS_AAPPtrtsFNDG
C3537035,C1320226,TREATS,kinase inhibitor,Incubation period,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3537035,C4054479,TREATS,kinase inhibitor,Molecular Response,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3658706,C3272283,TREATS,pembrolizumab,American College of Cardiology/American Heart Association Lesion Complexity Score C,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3658706,C4054275,TREATS,pembrolizumab,PD-L1 Overexpression,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3818725,C0150312,TREATS,"corticotropin, human",Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3818725,C0240341,TREATS,"corticotropin, human",Micrographia,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3818725,C4086268,TREATS,"corticotropin, human",Exacerbation,aapp,fndg,2,TREATS_AAPPtrtsFNDG
C3849701,C0574941,TREATS,"interleukin 18 protein, human",Inflamed joint,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3849701,C4321237,TREATS,"interleukin 18 protein, human",High Level,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3887822,C0150312,TREATS,visilizumab,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3891304,C0439663,TREATS,"Cathelicidin LL-37, human",Infected,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C3891304,C1545588,TREATS,"Cathelicidin LL-37, human",Protection,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C4084937,C0085393,TREATS,Antimicrobial Peptide,Immunocompromised Host,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C4084937,C0150312,TREATS,Antimicrobial Peptide,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C4084937,C0221198,TREATS,Antimicrobial Peptide,Lesion,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C4086595,C0436345,TREATS,Monalizumab,Symptom severe,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C4277602,C0679250,TREATS,Butyrophilins,Disease Outcome,aapp,fndg,1,TREATS_AAPPtrtsFNDG
C4309315,C0150312,TREATS,MI-0701,Present,aapp,fndg,1,TREATS_AAPPtrtsFNDG
